In re Automotive Parts Antitrust Litigation: Involving alleged price-fixing conspiracies as to various automotive parts that are components of new motor vehicles. Partial settlements to date total more than $650 million.
In re Disposable Contact Lens Antitrust Litigation: Involving alleged conspiracy among contact lens manufacturers and the leading distributor to artificially inflate contact lens prices by collusively establishing “unilateral pricing policies.”
In re Keurig Green Mountain Single-Serve Coffee Antitrust Litigation: Involving monopolization claims against Keurig for allegedly obtaining an unlawful monopoly through a multifaceted scheme of anticompetitive acquisitions, exclusive dealing, and sham patent litigation.
In re Optiver Commodities Manipulation Antitrust Litigation: Settlement of almost $17 million pertaining to an alleged unlawful scheme to manipulate the trading prices of light sweet crude oil, heating oil, and gasoline futures contracts.
Anastasio, et al v. Total Gas & Power North America, Inc.: Involving an alleged unlawful trading scheme to manipulate the index settlement prices of natural gas as well as the prices of physical natural gas and natural gas futures contracts.
In re TriCor Indirect Purchaser Antitrust Litigation: $65.7 million settlement for claims that the price charged for Tricor was inflated because of anticompetitive conduct, including product hopping in order to unlawfully suppress generic competition. (Prior to joining Robins Kaplan LLP)
In re Buspirone Antitrust Litigation: $90 million settlement for claims that Bristol-Myers Squibb engaged in monopolistic and anticompetitive conduct in marketing BuSpar in order to unlawfully suppress generic competition. (Prior to joining Robins Kaplan LLP)
In re Warfarin Sodium Antitrust Litigation: $44.5 million settlement for claims that DuPont Pharmaceuticals Company made false representations in order to unlawfully suppress generic competition for Coumadin. (Prior to joining Robins Kaplan LLP)
In re Lorazepam and Clorazepate Antitrust Litigation: $147 million settlement for claims that Mylan Laboratories, Inc. implemented unlawful and anticompetitive price increases for generic versions of the anti-anxiety drugs Lorazepam and Clorazepate. (Prior to joining Robins Kaplan LLP)
In re Brand Name Prescription Drug Indirect Purchaser Antitrust Litigation: $65 million multi-state settlement on behalf of consumers injured by anticompetitive practices of pharmaceutical manufacturers. (Prior to joining Robins Kaplan LLP)
In re Natural Gas Commodity Litigation: $101 million settlement for manipulation of the price of natural gas futures contracts traded on the New York Mercantile Exchange. (Prior to joining Robins Kaplan LLP)
National Metals, Inc. v. Sumitomo Corporation, et al.: Over $90 million settlement on behalf of purchasers of copper products for claims of collusion and conspiracy to manipulate copper commodity prices on the London Metals Exchange, Ltd. (Prior to joining Robins Kaplan LLP)
In re Stock Exchange Options Trading Antitrust Litigation: $47 million settlement on behalf of a class of equity options purchasers injured by an alleged scheme to restrict the exchange listing of equity options. (Prior to joining Robins Kaplan LLP)
In re Aftermarket Filters Antitrust Litigation: Over $18 million settlement involving an alleged conspiracy to fix the prices of aftermarket automotive filters. (Prior to joining Robins Kaplan LLP)
Continental Seasonings, Inc. v. Pfizer, Inc. et al/In re Maltol Antitrust Litigation: $18 million settlement of food additive price fixing and market allocation claims against Pfizer, Inc. and others. (Prior to joining Robins Kaplan LLP)
In re Foundry Resins Antitrust Litigation: $14.2 million settlement for claims of bid-rigging, price fixing, and allocating customers in the market for foundry resins. (Prior to joining Robins Kaplan LLP)